2024-06-07 15:09:58 ET
More on Alnylam, Pliant, etc.
- Upcoming Pivotal HELIOS-B Data Looms Large For Alnylam's Valuation
- Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2024 Earnings Call Transcript
- Alnylam Pharmaceuticals, Inc. 2024 Q1 - Results - Earnings Call Presentation
- Pliant reports phase 2 data on idiopathic pulmonary fibrosis asset bexotegrast
- Alnylam Pharmaceuticals Non-GAAP EPS of -$0.16 beats by $0.32, revenue of $494.3M beats by $67.44M
Read the full article on Seeking Alpha
For further details see:
Alnylam, Pliant among stocks yet to face Q2 catalysts: Wells Fargo